WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia

BACKGROUND: The optimal strategy for vaccination to induce CD8(+) T cell responses against WT1 is not known. METHODS: A pilot randomized study in HLA-A02(+) patients to receive vaccination with WT1 in Montanide or in poly ICLC, a TLR3 agonist, to explore the novel immune adjuvant was conducted. Seve...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hongtao, Zha, Yuanyuan, Choudhury, Noura, Malnassy, Gregory, Fulton, Noreen, Green, Margaret, Park, Jae-Hyun, Nakamura, Yusuke, Larson, Richard A., Salazar, Andres M., Odenike, Olatoyosi, Gajewski, Thomas F., Stock, Wendy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765712/
https://www.ncbi.nlm.nih.gov/pubmed/29344432
http://dx.doi.org/10.1186/s40164-018-0093-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765712/
https://www.ncbi.nlm.nih.gov/pubmed/29344432
http://dx.doi.org/10.1186/s40164-018-0093-x

Ejemplares similares